Glaukos combines strong top‑line growth with a clearly differentiated position in ophthalmology, anchored by leadership in micro‑invasive glaucoma surgery and corneal cross‑linking. Its robust pipeline, expanding into sustained‑release implants and next‑generation corneal therapies, supports a multi‑year growth narrative. The company maintains solid liquidity and has reduced leverage over time, providing financial flexibility to continue funding R&D and commercialization. Deep surgeon relationships, a meaningful IP portfolio, and a focused, innovation‑driven culture further reinforce its strategic position.

The most significant risks stem from persistent and widening operating and net losses, alongside consistently negative operating and free cash flow. A growing accumulated deficit and declining equity highlight that value creation has so far been driven more by future potential than by current profitability. The business model remains dependent on external capital, making it sensitive to market conditions and investor appetite. Competitive pressures from larger ophthalmic companies, potential changes in reimbursement, and clinical or regulatory setbacks across its pipeline add further uncertainty.

Looking ahead, Glaukos appears well‑positioned to continue growing revenue as existing products penetrate further and new therapies come to market, especially in glaucoma and keratoconus. The central question is whether management can translate that growth into improving margins and eventually self‑funded operations by controlling costs, scaling efficiently, and securing favorable reimbursement. If the pipeline delivers and competitive pressures are managed, the company could emerge as a durable, specialized leader in ophthalmic procedures and procedural pharmaceuticals, but the path is likely to involve ongoing volatility in earnings and cash flow. Overall, the story is one of strong strategic positioning balanced against meaningful financial and execution risk.